CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 10.96: safe zone
- Interpretations3 currently firing — 1 · 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.00%Below 5Y avg (2.40%)
Annual Rate
CNY 0.58Paid annual
Payout Ratio
125.0%High
Payback Period
49.9 yr
Last Ex-Dividend
Jul 8, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.25BCNY484.87M · vs all stocks (USD)
Trailing P/E
27.86xvs Medical Devices peers
Revenue (TTM)
441.10MCNY65.84M · vs all stocks (USD)
Profit Margin
26.24%vs Medical Devices peers
Beta
0.3880xvs all stocks
52-Week Change
-3.14%vs all stocks
Market Capitalization
3.25BCNY484.87M · vs all stocks (USD)
Enterprise Value
2.22BCNY331.66M · vs all stocks (USD)
Trailing P/E
27.86xvs Medical Devices peers
Forward P/E
18.57xvs Medical Devices peers
Price to Sales (TTM)
7.36xvs Medical Devices peers
Price to Book (MRQ)
2.37xvs Medical Devices peers
Enterprise to Revenue
5.04xvs Medical Devices peers
Enterprise to EBITDA
23.75xvs Medical Devices peers
Gross Margin
58.99%vs Medical Devices peers
Profit Margin
26.24%vs Medical Devices peers
Operating Margin
8.39%vs Medical Devices peers
Return on Assets (TTM)
3.24%vs Medical Devices peers
Return on Equity (TTM)
8.43%vs Medical Devices peers
Revenue (TTM)
441.10MCNY65.84M · vs all stocks (USD)
Revenue per Share (TTM)
3.96CNYUpdated Sep 22, 2026Quarterly Revenue Growth
5.30%vs Medical Devices peers
Gross Profit (TTM)
255.53MCNY38.14M · vs all stocks (USD)
EBITDA (TTM)
136.89MCNY20.43M · vs all stocks (USD)
Net Income (TTM)
115.76MCNY17.28M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-18.30%vs Medical Devices peers
Operating Cash Flow (TTM)
89.64MCNY13.38M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-63.31MCNY-9.45M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5800CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
2.00%vs all stocks
5-Year Average Dividend Yield
2.40%vs all stocks
Payout Ratio
125.00%vs Medical Devices peers
Revenue
435.81MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
178.25MCNYFY2025 · Dec 31, 2025Gross Profit
257.56MCNYFY2025 · Dec 31, 2025Operating Income
100.18MCNY14.95M · vs all stocks (USD)
Pre-tax Income
128.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.15MCNYFY2025 · Dec 31, 2025Net Income
116.50MCNYFY2025 · Dec 31, 2025EBIT
128.96MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
144.16MCNYFY2025 · Dec 31, 2025Research & Development
74.49MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
27.42MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.50MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
309.91KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.04CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.04CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
112.02MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
112.02MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
116.50MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
83.40MCNYFY2025 · Dec 31, 2025Free Cash Flow
74.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
840.57MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
116.50MCNYFY2025 · Dec 31, 2025Other Non-cash Items
12.34MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-35.68MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.76MCNYFY2025 · Dec 31, 2025Capital Expenditures
-8.84MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.46BCNYFY2025 · Dec 31, 2025Sale of Investments
1.52BCNYFY2025 · Dec 31, 2025Other Investing Activity
5.69MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
57.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-111.87MCNYFY2025 · Dec 31, 2025Other Financing Charges
-663.25KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-112.54MCNYFY2025 · Dec 31, 2025Shares Outstanding
112.13MSharesUpdated Sep 22, 2026Float Shares
31.87MSharesUpdated Sep 22, 2026% Held by Insiders
72.71%vs all stocks
% Held by Institutions
3.22%vs all stocks
Total Cash (MRQ)
1.03BCNY154.08M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.21CNYUpdated Sep 22, 2026Total Debt (MRQ)
5.81MCNY867.18K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0043xvs Medical Devices peers
Current Ratio (MRQ)
6.58xvs Medical Devices peers
Book Value per Share (MRQ)
12.20CNYUpdated Sep 22, 2026Total Assets
1.59BCNY238.07M · vs all stocks (USD)
Total Current Assets
1.41BCNYFY2025 · Dec 31, 2025Total Liabilities
211.43MCNYFY2025 · Dec 31, 2025Total Non-current Assets
188.31MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
15.44MCNYFY2025 · Dec 31, 2025Total Current Liabilities
195.99MCNYFY2025 · Dec 31, 2025Cash
1.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.01BCNYFY2025 · Dec 31, 2025Other Short-term Investments
58.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
189.28MCNYFY2025 · Dec 31, 2025Inventory
129.35MCNYFY2025 · Dec 31, 2025Accounts Payable
93.94MCNYFY2025 · Dec 31, 2025Short-term Debt
1.28MCNYFY2025 · Dec 31, 2025Other Current Liabilities
61.12KCNYFY2025 · Dec 31, 2025Long-term Debt
1.86MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
112.13MCNYFY2025 · Dec 31, 2025Retained Earnings
327.97MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.38BCNY206.51M · vs all stocks (USD)
52-Week Low
25.03CNYUpdated Sep 22, 202652-Week High
44.78CNYUpdated Sep 22, 202652-Week Change
-3.14%vs all stocks
Beta
0.3880xvs all stocks
50-Day MA
28.29CNYUpdated Sep 22, 2026200-Day MA
31.51CNYUpdated Sep 22, 2026Avg 10-Day Volume
647.05KSharesUpdated Sep 22, 2026Avg 30-Day Volume
867.12KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.04CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 10.96: safe zoneNotable
Altman Z-Score: 10.96
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
PLANET Technology Corporation
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh Dividend Payout With FCF And Equity RatioMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Sichuan Baicha Baidao Industrial Co., Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh Dividend Payout With FCF And Equity RatioMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Jiangxi JDL Environmental Protection Co. Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh Dividend Payout With FCF And Equity RatioMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities